Kristin K.Zinsmaster


Minneapolis + 1.612.217.8861

Kristin Zinsmaster helps companies of all kinds successfully navigate complex criminal and civil litigation, enforcement actions, and investigations. She has worked on matters at every stage — from internal investigation to discovery to jury trial — in state and federal courts.

Kristin assists clients in many and varied industries, with particular focus on those doing business in the areas of health care and financial services. Her experience in litigation and investigations encompasses a range of subject areas, including business torts and contract disputes, fraud and embezzlement, federal securities law, shareholder derivative actions, anticorruption (FCPA and U.K. Bribery Act), and the False Claims Act.

Prior to joining Jones Day in 2016, Kristin practiced law at another firm in Minneapolis. During this time she participated in the investigation and litigation of securities and shareholder derivative matters in state and federal courts for a large medical device manufacturer. The majority of these matters resulted in unequivocal victories. Through this work, Kristin gained extensive experience in special litigation committee (SLC) investigations. She also devoted a significant portion of her practice to assisting clients in the financial services industry, defending against SEC and FINRA inquiries and an enforcement action brought by the United States Commodities Futures Trading Commission.

Kristin maintains a sizeable pro bono practice, devoted primarily to representing defendants in the District of Minnesota who qualify for the services of the Federal Defender. Kristin is a former collegiate athlete and serves on the board of directors of CycleHealth, an organization devoted to kids' wellness.


  • Global healthcare company obtains declinations from DOJ and SEC after multi-year investigation into corruption in Asia and EuropeJones Day obtained declinations from DOJ and the SEC on behalf of a global healthcare company that was under investigation for allegations of making improper payments in Asia and Europe.
  • Additional Publications

    • June 27, 2012
      Obligation To Indemnify Executive Accused of Criminal Conduct
    • December 3, 2015
      Novartis Pharmaceuticals Settles $390MM FCA Allegations
    • March 16, 2018
      Public Corruption Prosecutions in the McDonnell Era, Expert Guides


    In re the Welfare of Due Process


    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.